Can-fite Biopharma vs Clene
Can-fite Biopharma is the larger business, with $405,000 of revenue in fiscal 2025 against $200,000 for Clene (2.0 times as much). Can-fite Biopharma grew faster (-39.9% against -41.5%). Can-fite Biopharma kept more of each dollar of sales as profit: a net margin of -2426.7% against -13086.5%.
| Latest fiscal year | Can-fite BiopharmaCANF, 2025 | CleneCLNN, 2025 |
|---|---|---|
| Revenue | $405,000 | $200,000 |
| Revenue growth | -39.9% | -41.5% |
| Net income | −$9.8m | −$26.2m |
| Operating margin | — | — |
| Net margin | -2426.7% | -13086.5% |
| Return on equity | -178.2% | — |
| Free cash flow | −$9.0m | −$18.6m |
| Cash | $5.5m | $5.2m |
| Total debt | $0 | $17.8m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 79 |
| Market value | $2.1m | $47.9m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 62 sales |